

**6<sup>th</sup> Early Detection Research Network (EDRN) Scientific  
Workshop  
19<sup>th</sup> EDRN Steering Committee Meeting  
August 31 – September 3, 2009  
Doubletree Hotel Bethesda  
Bethesda, Maryland**

**EDRN Prostate/Urologic Cancers Collaborative Group Meeting**

**Wednesday, September 2, 2009  
2:00 – 6:00 p.m.  
Balance Room**

**Chairs:**

- William Grizzle, M.D., Ph.D., University of Alabama at Birmingham
- Jacob Kagan, Ph.D., M.Sc., National Cancer Institute

**Agenda**

- 2:00 – 2:10 p.m.      Welcome
- William Grizzle, M.D., Ph.D., University of Alabama at Birmingham
  - Jacob Kagan, Ph.D., M.Sc., National Cancer Institute
- Omic Approaches to Biomarker Discovery**
- 2:10 – 2:20 p.m.      Opportunities and Challenges in Application of the Epigenetic Markers for Detection of Urological Cancers  
Paul Cairns, Ph.D., Fox Chase Cancer Center
- 2:20 – 2:30 p.m.      Proteomics Approaches for Biomarkers Discovery  
John Semmes, Ph.D., Eastern Virginia Medical School
- 2:30 – 2:40 p.m.      Glycoproteins and Glycosylation Patterns: A New Paradigm for Biomarker Discovery  
Hui Zhang, Ph.D., Johns Hopkins University
- 2:40 – 2:50 p.m.      Metabolomics Profiling of Prostate Cancer  
Chris Beecher, Ph.D., University of Michigan
- 2:50 – 3:00 p.m.      Ligand-Targeted Nanoparticles for Prostate Cancer Diagnosis  
Steven S. Smith, Ph.D., City of Hope

**6<sup>th</sup> Early Detection Research Network (EDRN) Scientific  
Workshop  
19<sup>th</sup> EDRN Steering Committee Meeting  
August 31 – September 3, 2009  
Doubletree Hotel Bethesda  
Bethesda, Maryland**

**EDRN Prostate/Urologic Cancers Collaborative Group Meeting**

- 3:00 p.m. – 3:15 p.m.    Discussion  
*Moderators:*
- William Grizzle, M.D., Ph.D., University of Alabama at Birmingham
  - Daniel Chan, Ph.D., Johns Hopkins University
- Reports on the EDRN GU Validation Studies**
- 3:15 – 3:25 p.m.    Validation of ProPSA - EDRN and Beckman Coulter Collaborative Study
- Daniel Chan, Ph.D., Johns Hopkins University
  - Lori Sokoll, Ph.D., Johns Hopkins University
- 3:25 – 3:35 p.m.    Collaboration with the EDRN on a Validation Study – Lessons Learned: a Perspective of a Biotech Company  
Isaac A. Mizrahi, Ph.D., Beckman-Coulter, Inc.
- 3:35 – 3:45 p.m.    Update on Detection of Superficial Bladder Cancer Recurrence Based on Microsatellite Analysis
- Mark Schoenberg, M.D., Johns Hopkins University
  - Mark Thornquist, Ph.D., Fred Hutchinson Cancer Research Center
- 3:45 – 3:55 p.m.    MSA Study: Assay Validation
- Sanford Stass, M.D., University of Maryland School of Medicine
  - Sarah Helber, Ph.D., Commonwealth Biotechnologies, Inc.
- 3:55 – 4:10 p.m.    Discussion:  
*Moderators:*
- Jacob Kagan, Ph.D., M.Sc., National Cancer Institute
  - Ziding Feng, Ph.D., Fred Hutchinson Cancer Research Center
- 4:10 – 4:25 p.m.    Break**

**6<sup>th</sup> Early Detection Research Network (EDRN) Scientific  
Workshop  
19<sup>th</sup> EDRN Steering Committee Meeting  
August 31 – September 3, 2009  
Doubletree Hotel Bethesda  
Bethesda, Maryland**

**EDRN Prostate/Urologic Cancers Collaborative Group Meeting**

**Clinical Needs: Early Detection, Diagnosis,  
Detection of Aggressive Disease, Early Detection of  
Recurrence, and Risk Assessment**

- 4:25 – 4:35 p.m.      A Prostate Cancer Advocate Perspective  
Merel Nissenberg, J.D., NASPCC/Mountain  
Foundation for Lung Cancer
- 4:35 – 4:50 p.m.      Biomarkers for Risk Assessment  
Ian M. Thompson, M.D., University of Texas Health  
Sciences Center San Antonio
- 4:50 – 5:05 p.m.      Validation of Biomarkers for Early Detection,  
Diagnosis and Prognosis  
Alan W. Partin, M.D., Johns Hopkins University
- 5:05 – 5:15 p.m.      The Role of Reference Sets in Assay Validation  
Martin Sanda, M.D., Beth Israel Deaconess Medical  
Center/Harvard Medical School
- 5:15 – 5:30 p.m.      The Roadmap for Biomarkers Development and  
Validation  
Ziding Feng, Ph.D., Fred Hutchinson Cancer Research  
Center
- 5:30 – 6:00 p.m.      Discussion:  
*Moderators:*
- Martin Sanda, M.D., Beth Israel Deaconess Medical  
Center/Harvard Medical School
  - Jacob Kagan, Ph.D., M.Sc., National Cancer  
Institute

*Topics of Discussion:*

1. What are the clinical questions that should be addressed by the EDRN GU group?
2. What should be the focus of our group in the next round of the EDRN?
3. What are the challenges and what are the opportunities?
4. Reference specimens for biomarkers testing – do we have the specimens or will it require collection of new ones?

**6:00 p.m.**

**Adjourn**